Background-Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na + channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum. In this work, we tested whether truncated Na + channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF. Methods and Results-UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants. UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues. Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na + current. PERK activation destabilized SCN5A and, surprisingly, K v 4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA. PERK inhibition prevented the loss of fulllength SCN5A and K v 4.3 mRNA levels resulting from expressing Na + channel mRNA splice variants. Conclusions-UPR can be initiated by Na + channel mRNA splice variants and is involved in the reduction of cardiac Na + current during human HF. Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF. (Circ Arrhythm Electrophysiol. 2013;6:1018-1024 .) The online-only Data Supplement is available at http://circep.ahajournals.org/lookup/suppl/
H uman systolic heart failure (HF) is associated with decreased cardiac voltage-gated Na + channel current, 1 and these Na + channel changes have been implicated in the increased risk of sudden death in HF. [2] [3] [4] The cardiac Na + channel is a transmembrane protein composed of 4 homologous domains, each containing 6 transmembrane segments. SCN5A, encoding the α-subunit of the type V, voltage-gated cardiac Na + channel, consists of 28 translated exons. [5] [6] [7] Previously, we have shown that the Na + channel mRNA is alternatively spliced, with 2 SCN5A splicing variants (E28C and E28D) increasing in HF because of an angiotensin II (AngII)-or hypoxia-mediated increase in the splicing factor complex RNA binding motif protein 25/LUC7-Like 3 (RBM25/LUC7L3). 7 These variants cause a reading frame shift, resulting in premature stop codons, and encode cardiac Na + channels truncated before the pore-forming segment of domain IV of the channel. These variants cannot form functional channels and reduce Na + current to a greater extent than their percentage of the total SCN5A mRNA (ie, a dominant negative effect). 6 The mechanism of this dominant negative effect is unclear.
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The unfolded protein response (UPR) is a series of interrelated signaling pathways that occur when endoplasmic reticulum (ER) experiences excess secretory load, accumulates misfolded proteins, or is subject to other pathological conditions. UPR acts on several levels: it rapidly attenuates general protein synthesis, induces the expression of ER chaperone proteins, and enhances the degradation of misfolded proteins. [8] [9] [10] These changes are presumably designed to restore protein folding and ER health. There seem to be 3 main sensor proteins that activate the UPR. [8] [9] [10] Among these main ER stress sensors, protein kinase R-like ER kinase (PERK)-mediated UPR has been shown to be present in cardiomyocytes. 11 In the heart, the UPR plays a role during development, hypertrophy, ischemia, and HF. 11 HF is associated with hypoxia, elevated AngII, and increased catecholamines, [12] [13] [14] [15] [16] all of which have been shown to activate the UPR. [17] [18] [19] [20] In this work, we investigated the role of the UPR in mediating the Na + channel downregulation observed in HF.
Methods
Methods are described briefly below and reviewed in detail in the online-only Data Supplement.
Differentiation and Culture of Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes (hiPSC-CMs)
The human iPS cell line, DF19-9-11T, 21 was differentiated into CMs using the matrix sandwich method. 22 CMs differentiated for 30 days were used in this study. 22
Human Heart Tissue Samples
Human heart tissue samples were composed of end-stage cardiomyopathy hearts (n=10) and nonfailing control hearts (n=6). Normal human ventricular tissue was kindly offered by Dr J. Andrew Wasserstrom (Northwestern University, Chicago, IL). The control RNA sample was obtained from Clontech (Mountain View, CA). Samples were analyzed under University of Illinois at Chicago Institutional Review Board approval (Protocol 2009-0881).
Real-Time Polymerase Chain Reaction Quantification
Total RNA was isolated from cultured cells and human ventricular tissue using the RNeasy Mini Kit and RNeasy Lipid Tissue Mini Kit, respectively (Qiagen, Valencia, CA). The amplification conditions were a holding stage of 95°C for 20 minutes and 40 cycles at 95°C for 30 s and 60°C for 60 s. 7 
Transfection and Infection Assays
C-terminal green fluorescent protein (GFP)-tagged E28C and E28D variant constructs were transduced into hiPSC-CMs to overexpress E28C or E28D. An empty vector and a vector expressing only the fluorescent marker were used as controls.
Electrophysiology
Na + channel currents were measured from hiPSC-CMs by using the whole-cell patch-clamp technique in the voltage-clamp configuration at room temperature.
Statistics
All data are presented as means and the 95% confidence intervals (95% CI). Means were compared using unpaired Student t test or ANOVA. Time-dependent variables were tested by repeated measures ANOVA. A probability value of P<0.05 was considered statistically significant. Box and whisker plots show the median, second quartile, and 1.5 interquartile ranges. Line graphs with error bars are used to compare changes with time among multiple quantitative variables.
Results

UPR Components Were Upregulated in Human HF
To assess UPR activation in human HF, the expressions of the major UPR pathway components were evaluated by Western blot and qPCR. Compared with normal human heart tissue, the relative mRNA abundances of PERK, CCAAT/enhancerbinding protein homologous protein (CHOP), and calreticulin were increased by 1.82-fold (95% CI 1.76, 1.88; P<0.001), 2.22-fold (95% CI 2.14, 2.29; P<0.001), and 2.47-fold (95% CI 2.39, 2.55; P<0.001) in HF tissue, respectively ( Figure 1A ). mRNA findings were correlated with protein expression by Western blots. Representative Western blots are shown in Figure 1B . Compared with the control group, Western blot quantification showed that PERK, CHOP, and calreticulin were increased by 1.63-fold (95% CI 1.60, 1.65; P<0.001), 1.86-fold (95% CI 1.83, 1.89; P<0.001), and 2.10-fold (95% CI 2.06, 2.13; P<0.001) in the HF tissue samples (based on 3 replications for each group).
SCN5A Splice Variants Activate UPR
We tested whether the presence of SCN5A splice variants could induce PERK. hiPSC-CMs were used because abnormal SCN5A splicing has not been shown to occur in species other than humans and primates. 6 AngII and hypoxia are common pathogenic factors in HF. 12 We have shown that each increases the SCN5A variants by upregulating the splicing complex RBM25/LUC7L3, 7 and we used each as upstream A, Hypoxia, AngII (200 nmol/L), or overexpression of variant E28C or E28D constructs reduced full-length SCN5A mRNA. In each case, this reduction was inhibited by anti-PERK shRNAmir. Preinfection by scrambled shRNA had no effect on the SCN5A mRNA reduction by any treatment. Quantitative polymerase chain reaction measurements by 3 duplicates are shown at 24 hours in each treatment group and normalized by β-actin (*P<0.05 compared with control group, n=5 for each experimental group). PERK-mediated mRNA decay assays for SCN5A, K v 4.3, and transient receptor potential cation channel M7 (TRPM7) are shown in B-D, respectively. Control (closed squares), AngII-treated (200 nmol/L, inverted triangles), AngII-treated with preinfection by anti-PERK shRNAmir (closed diamonds), and AngIItreated with preinfection by scrambled shRNA (closed circles) groups are shown. mRNA was harvested for each group at 0, 6, 12, and 24 hours. The target genes were measured by qPCR and normalized to β-actin. The error bars in B-D represented SE. AngII treatment reduced SCN5A (P=0.019, n=5 for each experimental group; B) and Kv4.3 (P=0.042, n=5 for each experimental group; C) mRNA stability when compared with control while having no effect on TRPM7 (P=0.078, n=5 for each experimental group; D). Preinfection by pGIPZ lentiviral anti-PERK shRNAmir but not scrambled shRNA could prevent mRNA instability (P=0.027, n=5 for each experimental group).
stimuli to induce abnormal SCN5A mRNA splicing. The lack of abnormal splicing in rodents is because of a lack of upregulation of the RBM25/LUC7L3 splicing complex for unknown reasons.
hiPSC-CMs were divided into 4 experimental groups: untreated control, AngII treated (200 nmol/L), and SCN5A variant E28C and variant E28D overexpression groups. The AngII dose was chosen based on previous experiments showing a maximal effect on variant abundance. 7 Cells were harvested from each experimental group at 48 hours, and total mRNA was extracted. The expression of PERK was examined by qPCR in each group. The results showed that PERK mRNA was increased in each experimental group compared with control, ranging from 2.5-to 2.6-fold depending on the group (P=0.012 for each group; Figure 2A ). Western blot revealed that PERK was increased in each experimental group, ranging from 1.5-to 2.5-fold depending on the group (P=0.033 for each group). The representative Western blots and quantification (based on 3 replications for each group) are shown in Figure 2B . However, overexpression of fulllength SCN5A did not upregulate PERK ( Figure I 
PERK Causes SCN5A Variant-Mediated Downregulation of the Full-Length SCN5A mRNA
Activated PERK phosphorylates eukaryotic Initiation Factor 2α (eIF2α), increasing mRNA instability by inhibiting ribosomal association. 23, 24 To test whether PERK activation affected SCN5A stability, hiPSC-CMs cells were divided into 3 experiment groups: AngII-treated cells, AngII-treated cells preinfected by pGIPZ lentiviral anti-PERK shRNAmir, and AngII-treated cells preinfected by scrambled shRNA. AngII (200 nmol/L) treatment was given to all experiment groups for 48 hours until cell harvesting. The infection rate was >90%, evaluated by the ratio of GFP-positive cells (pGIPZ lentiviral infected cells) to total cells. PERK knockdown efficiency was 60.0% (95% CI 55.3%, 64.7%; P=0.017) at 48 hours, evaluated by Western blot ( Figure II in the online-only Data Supplement). Compared with the AngII-treated group, the expression of the full-length SCN5A mRNA was increased by 1.42-fold (95% CI 1.40, 1.44; P=0.031) when cells were preinfected by anti-PERK shRNA. Scrambled shRNA did not change the AngII effect. The results indicated that AngIImediated SCN5A mRNA downregulation was dependent on PERK ( Figure 3A) . Similar results were observed when hiPSC-CMs were transfected with variant E28C or E28D constructs rather than treated with AngII. Full-length SCN5A was increased by 1.54-fold (95% CI 1.49, 1.59; P=0.044) and 1.47-fold (95% CI 1.38, 1.56; P=0.042), respectively, after preinfected with anti-PERK shRNA at 48 hours. Again, scrambled shRNA did not prevent the effect of the variants.
The specificity of the PERK effect on the downregulation of full-length SCN5A was evaluated by analyzing mRNA stability of 2 other channels regulated by AngII, K v 4.3, 25, 26 and transient receptor potential cation channel M7 (TRPM7). 22 These 2 channels were chosen as representatives because both are present in cardiomyocytes, 25, 26 and because Kv4.3 but not TRPM7 is known to be regulated in HF. 27 cells preinfected by pGIPZ lentiviral anti-PERK shRNAmir, and AngII-treated (200 nmol/L) cells preinfected by a vector containing scrambled shRNA. Except for the control groups, AngII treatments were given to the all experiment groups for 24 hours. mRNA was extracted at 0, 6, 12, and 24 hours after AngII treatment. Compared with the untreated cells, the expressions of both SCN5A ( Figure 3B ) and K v 4.3 ( Figure 3C ) were reduced ≈60%, 70%, and 70% at 6, 12, and 24 hours, respectively, when cells were treated with AngII or treated with AngII and preinfected by scrambled shRNA, whereas the expression of both SCN5A and K v 4.3 mRNAs were only reduced ≈20%, 30%, 30% at 6, 12, and 24 hours, respectively, when cells were treated with the anti-PERK shRNAmir, implying that the downregulation of PERK prevented mRNA decay of both SCN5A and K v 4.3. There was no statistical difference between the SCN5A and K v 4.3 mRNA decay curves before or after PERK inhibition (P=0.108), suggesting that both ion channels mRNA abundances were affected equivalently by PERK activation. There is no statistical difference in TRPM7 mRNA ( Figure 3D ) between the different treatment groups and at the various time points (P=0.075), suggesting that the PERK-mediated UPR showed some degree of specificity.
Truncated Na + Channels Were Localized to the Endoplasmic Reticulum (ER)
To examine the subcellular localization of truncated Na + channels, we overexpressed pEGFP-C1-SCN5A E28C and pEGFP-C1-SCN5A E28D in hiPSC-CMs ( Figure 4A ). Detailed information of both constructs is shown in Figure 4B .
In each case, the truncation variant was linked to GFP at the 5′ end. Therefore, green immunofluorescence indicated the location of truncated Na + channel encoded by E28C or E28D. The transfected cells were studied at 48 hours and stained with the ER marker calreticulin (in red, Figure 4A ). The merged images showed the colocalization of truncated Na + channel variants with calreticulin. This pattern was distinct from the membrane localization of full-length SCN5A ( Figure III in the online-only Data Supplement).
PERK Activation Reduces Na + Current
The functional consequence of PERK-mediated destabilization of SCN5A mRNA was tested by measuring Na + current in hiPSC-CMs. The cells were divided into 3 experimental groups: control, AngII-treated (200 nmol/L), and AngII-treated (200 nmol/L) cells preinfected by anti-PERK shRNA. Cells were used for measuring Na + current at 48 hours. The representative current traces from Figure 6 . A summary of the effects of abnormal Na + channel splicing in end-stage, systolic heart failure (HF). AngII and hypoxia are 2 regulators for RNA binding motif protein 25/LUC7 like 3 (RBM25/ LUC7L3)-mediated SCN5A splicing regulation. 7 HF is associated with an increase in Na + channel mRNA variants resulting from splicing at cryptic splice sequences in the terminal exon of SCN5A (ie, exon 28). These variants encode nonfunctional cardiac Na + channels. Variant levels reach greater that >50% of the total SCN5A mRNA. 6, 7 Abnormal mRNA splicing and variant-mediated UPR activation contribute to a decreased in full-length Na + channel mRNA, protein, and current in HF.
each group are shown in Figure 5 . The peak Na + current density at −30 mV in AngII-treated human cardiomyocytes was reduced by 62% (95% CI 58%, 66%; P=0.027) when compared with control cells. The effect of AngII on peak current was abrogated by the pretreatment of anti-PERK shRNA. Scrambled shRNA lentiviral particles had no effect on Na + channel current regulation by AngII (P=0.091, data not shown). As found previously, gating changes could not explain the magnitude of peak current changes seen (Table I and Figure IV in the online-only Data Supplement). 6
Discussion
Recently, we reported that 2 SCN5A mRNA splicing variants are upregulated in end-stage, systolic human HF tissue. These variants reach greater that >50% of the total SCN5A mRNA and do not produce functional channels. 6, 7 The expression of these variants in cells stably expressing the full-length channel causes a dose-dependent reduction in the transcripts of fulllength SCN5A, as well as the reduction in functional Na + current expression. 6, 7 Moreover, a mutation in a single allele of SCN5A mimicking a variant causes an 86% reduction in Na + current, >50% predicted reduction. 6 These data suggest that the variants have a dominant negative effect on the full-length channel, but the underlying mechanism is unclear. We hypothesized that UPR might be responsible for the variant-initiated, dominant negative reduction in Na + current. Our data show that UPR was activated in end-stage, systolic human HF. Although the human heart experiments do not establish which cell type is experiencing UPR activation, the cardiomyocyte experiments establish that UPR regulates Na + current in these cells. We show that truncated Na + channels, encoded by SCN5A variants, become trapped in the ER and activate the UPR. UPR activation resulted in decreased fulllength Na + channel mRNA, protein, and current. Previously, we have shown that full-length, C-terminal GFP-tagged SCN5A targets to the sarcolemma and functions normally, and untagged variants cause a dose-dependent reduction in SCN5A transcript, 6 making unlikely the possibility that UPR activation was related to GFP tagging of the variants. Moreover, elevated AngII and hypoxia, conditions that exist in HF 12 and are known to increase the SCN5A truncation variants, 6,7 had similar effects on PERK activation, suggesting that variant induction may contribute to the UPR with these stimuli. Inhibition of PERK prevented full-length SCN5A mRNA degradation and Na + current reduction, suggesting that UPR activation is downstream of variant translation and required for the variant-mediated reduction in Na + current.
UPR activation is thought to cause translational inhibition affecting a significant number of, but not all, proteins. The spectrum of proteins affected is unknown as is the mechanism by which some proteins avoid UPR-mediated inhibition. In our case, we showed that AngII-induced PERK activation was responsible for degradation of mRNA encoding the K + channel α-subunit, K v 4.3, which encodes the cardiac transient outward current. Because this K + channel is downregulated in HF or by AngII, [27] [28] [29] [30] [31] [32] it seems likely that a mechanism of this downregulation is UPR activation. It is possible that UPR activation explains, at least partially, the coregulation of K v 4.3 and Na + channels observed in HF. 33 Another AngII-regulated ion channel, TRPM7, was not affected by PERK regulation, confirming that UPR has certain selectivity. Although we did not measure currents of K v 4.3 or TRPM7, the changes in mRNA are consistent with those seen in HF. 25, 32, 33 Therefore, the results make it clear that UPR does not affect all protein expression equally, but the basis for selectivity between proteins is unknown.
In summary, this and our previous results 6, 7 suggest that the reduction in Na + current during systolic human HF results in part from abnormal SCN5A mRNA splicing to produce nonfunctional channels that become trapped in the ER and activate the UPR. UPR activation leads to destabilization of the remaining full-length SCN5A mRNA, exacerbating the reduction in Na + currents. Figure 6 shows a current hypothesis for the effect of HF on SCN5A mRNA handling based on this and previous work. Although we were not able to test the extent to which the Na + channel reductions mediated in this way contribute to arrhythmia because the splice variants occur only in humans, 6 the changes in current were in the range known to contribute to arrhythmic risk. The broad nature of the UPR effect may contribute to the downregulation of other critical proteins in end-stage, systolic HF. 
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